Canaccord Genuity analyst Sumant Kulkarni reiterated a Buy rating and $350.00 price target on Biogen (NASDAQ: BIIB), citing the FDA ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Biogen (BIIB) PT Raised to $360 at Oppenheimer as FDA Accepts Adu BLA with Priority ReviewAugust 7, 2020 10:35 AM Alzheimer's drug from Biogen to get speedy U.S. reviewAugust 7, 2020 10:31 AM Biogen (BIIB) call put ratio 3.3 calls to 1 put after FDA accepts aducanumab with priority reviewAugust 7, 2020 10:15 AM Pre-Open Stock Movers 08/07: (TRUE) (GRPN) (STMP) Higher; (AYX) (DDOG) (ILMN) Lower (more...)August 7, 2020 9:26 AM Biogen (BIIB) Could Trade Up to ~$350/Share Into FDA Adu Decision - GuggenheimAugust 7, 2020 8:45 AM Biogen (BIIB) call put ratio 3.4 calls to 1 put into FDA accepts aducanumab with priority reviewAugust 7, 2020 8:08 AM Biogen (BIIB) Announces FDA Accepts its Aducanumab Biologics License Application for Alzheimer's Disease with Priority ReviewAugust 7, 2020 7:32 AM FDA Accepts Biogen’s Aducanumab Biologics License Application for Alzheimer's Disease with Priority ReviewAugust 7, 2020 7:31 AM